home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3157.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
36 lines
Document 3157
DOCN M94A3157
TI Why isn't increased survival enough?
DT 9412
AU Wilson AD; Wellcome Foundation Ltd, Beckenham, Kent.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):14 (abstract no. 030D). Unique
Identifier : AIDSLINE ICA10/94369418
AB This presentation will review the four main reasons for applying
economic analyses to the field of HIV and AIDS healthcare. These are: 1.
Current projections of the growing number of people who may be affected
by HIV/AIDS worldwide. 2. The predicted large degree of dependence on
healthcare systems of people with HIV/AIDS who will require prolonged
treatment, nursing and terminal care. 3. The impact on healthcare
budgets of providing care to people with HIV/AIDS. 4. The current focus,
by many industrialised countries, on containing the costs of healthcare.
The presentation will examine the meaning of cost effectiveness in a
healthcare setting. Cost-effectiveness is one of a family of methods for
assessing costs and benefits in terms of efficacy or value for money.
Currently, cost-effectiveness data exists only for Zidovudine (Retrovir,
AZT) monotherapy and the focus of this presentation will be a review of
the existing literature. Recently completed work including the results
of the economic evaluation from the Cost-Effectiveness of AIDS Therapy
(CEAT) Study is discussed. The potential of these studies to contribute
to the information available for decision-makers is assessed. Also,
using gap analysis, we will identify the future direction of economic
evaluation work required, with consideration for different therapeutic
options such as combination therapy.
DE *Cost of Illness Cost-Benefit Analysis Drug Costs Health
Services/*ECONOMICS/SUPPLY & DISTRIBUTION/UTILIZATION Human HIV
Infections/DRUG THERAPY/*ECONOMICS Zidovudine/THERAPEUTIC USE MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).